Earnings ·
Braveheart Bio reports $15M net loss, initiates Phase 3 LIONHEART-HCM trial for BHB-1893 in oHCM
BRVEBraveheart Bio, Inc.
Braveheart Bio, Inc. reported unaudited financial results for the quarter ended June 30, 2026, reporting a net loss of $15.0 million ($2.51 per share) and cash and cash equivalents of $122.8 million. The company initiated its Phase 3 LIONHEART-HCM trial for BHB-1893 in obstructive hypertrophic cardiomyopathy (oHCM), with first patient dosing expected later this year, while planning to start the NOBLEHEART-HCM Phase 3 trial for non-obstructive HCM (nHCM) in early 2027. Braveheart Bio completed an initial public offering in August 2026, raising approximately $404.5 million in net proceeds, bringing total cash resources to roughly $527.3 million on an as-adjusted basis and extending its funding runway into 2029. The company is a clinical-stage biopharmaceutical firm developing therapies for hypertrophic cardiomyopathy.